Researchers trace HIV evolution in North America (Update)

April 24, 2014, Simon Fraser University
Zabrina Brumme's health sciences lab. Members of Zabrina Brumme's health sciences lab. (l-r) Laura Cotton, Zabrina Brumme, Anh Q. Le, Xiaomei (Tallie) Kuang

A study tracing the evolution of HIV in North America involving researchers at Simon Fraser University has found evidence that the virus is slowly adapting over time to its human hosts. However, this change is so gradual that it is unlikely to have an impact on vaccine design.

"Much research has focused on how HIV adapts to antiviral drugs—we wanted to investigate how HIV adapts to us, its human hosts, over time," says lead author Zabrina Brumme, an assistant professor in SFU's Faculty of Health Sciences.

The study, published today in PLOS Genetics, was led by Brumme's lab in collaboration with scientists at the BC Centre for Excellence in HIV/AIDS, UBC, and sites across the U.S. including Harvard University, the New York Blood Center and the San Francisco Department of Public Health.

"HIV adapts to the immune response in reproducible ways. In theory, this could be bad news for host immunity—and vaccines—if such mutations were to spread in the population," says Brumme. "Just like transmitted drug resistance can compromise treatment success, transmitted immune escape mutations could erode our ability to naturally fight HIV."

Researchers characterized HIV sequences from patients dating from 1979, the beginning of the North American HIV epidemic, to the modern day.

The team reconstructed the epidemic's ancestral HIV sequence and from there, assessed the spread of immune escape mutations in the population.

"Overall, our results show that the virus is adapting very slowly in North America," says Brumme. "In parts of the world harder hit by HIV though, rates of adaptation could be higher."

The study ends with a message of hope, Brumme adds. "We already have the tools to curb HIV in the form of treatment—and we continue to advance towards a vaccine and a cure. Together, we can stop HIV/AIDS before the virus subverts host immunity through population-level adaptation."

Numerous SFU researchers contributed to the analysis, which required the careful recovery of viral RNA from historic specimens followed by laboratory culture. A trio of SFU graduate students, including health sciences student Laura Cotton, shared the lead author role.

"It was painstaking work," says Cotton, "but it was fascinating to study these isolates in the lab, knowing that they had played an important role in the history of HIV on our continent."

Explore further: Scientists find the invisibility cloak that shields HIV-1 from the immune system

More information: Cotton LA, Kuang XT, Le AQ, Carlson JM, Chan B, et al. (2014) Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. PLoS Genet 10(4): e1004295. DOI: 10.1371/journal.pgen.1004295

Related Stories

Scientists find the invisibility cloak that shields HIV-1 from the immune system

November 21, 2013
Of the two major types of HIV, only one, HIV-1, typically causes AIDS in infected people who don't receive treatment. A study published by Cell Press November 21st in the journal Immunity reveals how HIV-1 escapes detection ...

Harnessing immune cells' adaptability to design an effective HIV vaccine

March 21, 2013
In infected individuals, HIV mutates rapidly to escape recognition by immune cells. This process of continuous evolution is the main obstacle to natural immunity and the development of an effective vaccine. A new study published ...

HIV vaccine research must consider various immune responses

April 3, 2014
Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility ...

Transplant drugs may help wipe out persistent HIV infections

April 3, 2014
New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of Transplantation, suggest ...

Cutting HIV in drug users can benefit others' AIDS mortality

March 26, 2014
(HealthDay)—Efforts to curb HIV transmission among people who inject drugs (PWID) and non-injecting drug users (NIDUs) may reduce AIDS and AIDS-related mortality among heterosexuals, according to a study published in the ...

HIV treatment while incarcerated helped prisoners achieve viral suppression

March 31, 2014
Treating inmates for the human immunodeficiency virus (HIV) while they were incarcerated in Connecticut helped a majority of them achieve viral suppression by the time they were released.

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.